JP6527534B2 - ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 - Google Patents

ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 Download PDF

Info

Publication number
JP6527534B2
JP6527534B2 JP2016573017A JP2016573017A JP6527534B2 JP 6527534 B2 JP6527534 B2 JP 6527534B2 JP 2016573017 A JP2016573017 A JP 2016573017A JP 2016573017 A JP2016573017 A JP 2016573017A JP 6527534 B2 JP6527534 B2 JP 6527534B2
Authority
JP
Japan
Prior art keywords
ring
amino
methoxy
quinolyl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524668A (ja
JP2017524668A5 (OSRAM
Inventor
エナ，ザビエル アギーレ
エナ，ザビエル アギーレ
サンタマリーナ，フレン オヤルサバル
サンタマリーナ，フレン オヤルサバル
カルドーソ，フェリペ プロスペル
カルドーソ，フェリペ プロスペル
グラシア，マリア オブドゥリア ラバル
グラシア，マリア オブドゥリア ラバル
マドス，フアン ロベルト ロドリゲス
マドス，フアン ロベルト ロドリゲス
ホセ エネリス，エドゥルネ サン
ホセ エネリス，エドゥルネ サン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Para La Investigasion Medica Aplicada
Original Assignee
Fundacion Para La Investigasion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investigasion Medica Aplicada filed Critical Fundacion Para La Investigasion Medica Aplicada
Publication of JP2017524668A publication Critical patent/JP2017524668A/ja
Publication of JP2017524668A5 publication Critical patent/JP2017524668A5/ja
Application granted granted Critical
Publication of JP6527534B2 publication Critical patent/JP6527534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016573017A 2014-06-16 2015-03-30 ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 Active JP6527534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382230 2014-06-16
EP14382230.2 2014-06-16
PCT/EP2015/056860 WO2015192981A1 (en) 2014-06-16 2015-03-30 Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases

Publications (3)

Publication Number Publication Date
JP2017524668A JP2017524668A (ja) 2017-08-31
JP2017524668A5 JP2017524668A5 (OSRAM) 2018-04-12
JP6527534B2 true JP6527534B2 (ja) 2019-06-05

Family

ID=51136403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573017A Active JP6527534B2 (ja) 2014-06-16 2015-03-30 ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物

Country Status (9)

Country Link
US (1) US9840500B2 (OSRAM)
EP (1) EP3154957B1 (OSRAM)
JP (1) JP6527534B2 (OSRAM)
CN (1) CN106536509B (OSRAM)
AU (1) AU2015276537B2 (OSRAM)
CA (1) CA2987978C (OSRAM)
DK (1) DK3154957T3 (OSRAM)
ES (1) ES2769648T3 (OSRAM)
WO (1) WO2015192981A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017102677A1 (en) * 2015-12-14 2017-06-22 Fundación Para La Investigación Médica Aplicada 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
KR20230130747A (ko) * 2016-04-15 2023-09-12 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US11278550B2 (en) 2016-05-17 2022-03-22 Duke University Compositions and methods for the treatment of Prader-Willi syndrome
US11433068B2 (en) * 2016-09-08 2022-09-06 The General Hospital Corporation Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex
EP4063358B1 (en) * 2016-12-22 2024-05-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2018119065A1 (en) 2016-12-22 2018-06-28 Asddr, Llc Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of phelan-mcdermid syndrome
US20200113901A1 (en) * 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
BR112019025770A2 (pt) 2017-06-09 2020-06-23 Global Blood Therapeutics, Inc. Compostos de azaindol como inibidores de histona metiltransferase
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
WO2019036384A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
EP3668863B1 (en) 2017-08-15 2025-03-19 Global Blood Therapeutics, Inc. Tricyclic compounds as histone methyl-transferase inhibitors
SG11202003225YA (en) * 2017-10-18 2020-05-28 Epizyme Inc Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
WO2019079607A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN THE TREATMENT OR PREVENTION OF BLOOD DISORDERS
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
WO2019243236A1 (en) 2018-06-18 2019-12-26 Fundación Para La Investigación Médica Aplicada New anticancer drug combinations
CN112390791B (zh) * 2019-08-14 2023-08-01 复旦大学 一类dna甲基转移酶1荧光探针及其用途
JP2023536634A (ja) * 2020-08-07 2023-08-28 アトス セラピューティクス，インコーポレイテッド 自己免疫疾患および癌の処置のための小分子
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
CN120965666A (zh) * 2025-10-21 2025-11-18 四川大学华西医院 一种喹啉类化合物、制备方法和用途及其药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001154A1 (en) * 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
CA2412345A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004056352A1 (en) * 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
US7314939B2 (en) * 2003-06-17 2008-01-01 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
CA2664631A1 (en) 2006-10-12 2008-04-17 David J. Bearss Quinoline derivatives for modulating dna methylation
CN101535295A (zh) * 2006-10-12 2009-09-16 休普基因公司 用于调节dna甲基化的喹啉衍生物
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
WO2010151791A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
CA2770753C (en) * 2009-08-12 2019-01-15 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
WO2011054433A1 (en) * 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
EP2828250B1 (en) 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
EP2918014B1 (en) * 2012-11-09 2018-10-31 OCT Circuit Technologies International Limited Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物

Also Published As

Publication number Publication date
AU2015276537A1 (en) 2017-01-05
CN106536509B (zh) 2020-06-09
CN106536509A (zh) 2017-03-22
CA2987978C (en) 2022-08-16
AU2015276537B2 (en) 2019-03-14
US20170121316A1 (en) 2017-05-04
WO2015192981A1 (en) 2015-12-23
US9840500B2 (en) 2017-12-12
JP2017524668A (ja) 2017-08-31
CA2987978A1 (en) 2015-12-23
EP3154957B1 (en) 2019-11-20
EP3154957A1 (en) 2017-04-19
DK3154957T3 (da) 2020-02-17
ES2769648T3 (es) 2020-06-26

Similar Documents

Publication Publication Date Title
JP6527534B2 (ja) ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物
JP6401773B2 (ja) Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
KR101873672B1 (ko) Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법
ES2360933T3 (es) Derivados de heteroarilo condensados.
AU2015239886B2 (en) Indole derivatives for use in medicine
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
JP5615902B2 (ja) イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
WO2016071283A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
AU2015341913A1 (en) Pharmaceutical compound
WO2003000660A1 (fr) Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
CN107531683B (zh) Usp7抑制剂化合物及使用方法
JP6795518B2 (ja) キナーゼを阻害する組成物及び方法
JP6667014B2 (ja) ピリミジン誘導体、その調製方法および医療での使用
US20130065883A1 (en) Triazolo [4, 5- B] Pyridin Derivatives
CN108602798A (zh) 作为dna甲基转移酶抑制剂的2,4,6,7-四元取代的喹啉化合物
EP3703684A1 (en) Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
JP2009532400A (ja) キナーゼ阻害剤としての３−非置換Ｎ−（アリール−もしくはヘテロアリール）−ピラゾロ［１，５−ａ］ピリミジン
RU2774952C2 (ru) Соединения
HK1248684B (en) Usp7 inhibitor compounds and methods of use
HK1217703B (en) Novel fused pyrimidine compound or salt thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190416

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190510

R150 Certificate of patent or registration of utility model

Ref document number: 6527534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250